Members:
Adrian Schwarzer, MD PhD (PI)
Marc-Jens-Kleppa, PhD (PostDoc)
Katrin Darm (TA)
Maria Wessels (Grad Student)
Julian Waclawski (Grad Student)
Max Schinke (Grad Student)
Research focus:
We are developing and utilizing advanced functional genetic tools to model and investigate hematological malignancies. To achieve this, we are combining a wide range of methods including bioinformatics, conditional gene expression, inducible RNAi, CRISPR-Cas9 screens, transgenic mouse strains, and homologous recombination using CRISPR-Cas9 and adeno-associated viruses (AAV). Using these tools, we are creating leukemia mouse models that more accurately replicate the complexity, diversity, and plasticity of these diseases. We then systematically study these models in vitro and in vivo using highthroughput techniques such as CRISPR screens, singlecell RNA sequencing, and targeted protein degradation to identify novel genetic dependencies that can be exploited as therapeutic targets.
Key techniques:
• Viral gene/shRNAmiR/sgRNA transfer, CRISPR- and shRNA screens
• Conditional gene-expression and knockdown using Tet/ERT/AID systems
• HDR-genome editing using CRISPR-Cas9 RNP and AAV6
• Leukemia mouse models based on genetically engineered hematopoietic stem cells
• Development of Full-spectrum Flow Cytometry assays for MRD in AML
